Health care stocks were advancing premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.
Novartis (NVS) will keep manufacturing treatments for malaria and leprosy even if regular orders stop due to global health funding cuts, Reuters reported, citing its global health president. The company's shares were down more than 2% pre-bell.
ImmunityBio (IBRX) stock was up more than 4% after the company reported a narrower Q1 net loss as revenue increased during the period.
Dr. Reddy's Laboratories (RDY) shares were up past 3% after the company posted higher fiscal Q4 earnings and revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.